Gene Editing Arrives: One Infusion to Lower LDL for Good? The headline is astounding— and paints a gloomy picture for the villains of heart disease.
Understanding true cardiac risk has always been one of the most satisfying diagnostic puzzles in my practice. For years we’ve had excellent tools—statins, ezetimibe, and the PCSK9 inhibitors like Repatha that work remarkably well by blocking the PCSK9 protein and letting the liver clear more LDL. But what if we could simply turn the PCSK9 gene off… permanently? It sounds like science fiction.
A May 2026 New England Journal of Medicine article on VERVE-102 just made that question a lot more real. VERVE-102 is an investigational base-editing therapy designed to durably inactivate the PCSK9 gene in the liver. In a phase 1 open-label study of 35 adults with heterozygous familial hypercholesterolemia or premature coronary disease, participants received a single intravenous infusion at one of several dose levels.
The results were striking and dosedependent: At the highest dose, circulating PCSK9 protein fell by a mean of 88% and LDL cholesterol dropped 62%—an absolute reduction of about 78 mg/dL.
Imagine watching your LDL cholesterol drop from 150 to 72 with a single infusion? Fifteen participants had at least one year of follow-up, and the reductions appeared durable throughout that period. Side effects were generally mild: some infusion-related reactions and mild liver-enzyme elevations. No doselimiting toxicities were observed.
In essence, this is the genetic equivalent of what Repatha does pharmacologically—except instead of repeated injections, the idea is a one-time edit that mimics the natural loss-offunction PCSK9 variants that are naturally protective, and potentially, a key genetic feature amongst centenarians.
Is this the beginning of treating high cholesterol the way we treat certain infections—with a single, durable intervention? We are still very early, and of course larger and longer studies are needed, but the concept is genuinely exciting and very feasible with modern technology. For the first time, we can see a future in which one of the most powerful modifiable drivers of atherosclerosis might be dialed down at the DNA level, once, and left alone.
As always, the art will be matching the right tool to the right patient at the right time. This clearly isn’t prime time just yet, but I’m beyond confident that this technology will redefine lipidology in our lifetime. Stay tuned!